MetaCap

MapLight Therapeutics (MPLT) vs PepGen (PEPG)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

PepGen (PEPG) has outperformed MapLight Therapeutics (MPLT) over the past year, losing 32.0% versus a loss of 57.5%. PepGen is the larger company by market cap ($356.3 million vs $330.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MPLT-57.54%PEPG-32.01%
+197%+54%-89%
Nov 21, 20251 yearNov 20, 2026
MPLT-64.89%PEPG-18.88%
+142%+31%-80%
Oct 27, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MPLT versus PEPG key metrics
MetricMPLTPEPG
Share price$5.94$3.78
Market cap$330.12M$356.31M
1-day change-7.48%-3.82%
YTD return-66.18%-41.94%
1-year return-57.54%-32.01%
EPS (TTM)$-6.07$-0.77
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-161.15M$-89.66M
52-week high$40.43$7.80
52-week low$5.93$1.31
Distance from 52-week high-85.31%-51.54%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+340.24%+263.76%
Average volume458.71K3.26M
Shares outstanding52.85M94.26M
Employees13353
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PEPG has outperformed MPLT by 25.5 percentage points over the past year.

About MapLight Therapeutics

MPLT stock →

MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 133 employees

About PepGen

PEPG stock →

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.

Health Care · Biotechnology: Pharmaceutical Preparations · 53 employees

MPLT vs PEPG FAQ

Which is bigger, MapLight Therapeutics or PepGen?

PepGen (PEPG) is larger, with a market capitalization of $356.31M compared with $330.12M for MapLight Therapeutics (MPLT).

Which stock has performed better over the past year, MPLT or PEPG?

PEPG returned -32.01% over the past 12 months, compared with -57.54% for MPLT (price return, excluding dividends). Past performance does not predict future results.

Are MapLight Therapeutics and PepGen in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons